Does Cesarean Section Scar Defect (Niche) Affect Implantation Rate?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lilia Margolis-Dorfman, M.P.H
- Phone Number: +972-3530-4948
- Email: lilia.mdorfman@gmail.com
Study Contact Backup
- Name: Roy Mashiach, M.D
- Phone Number: +972-35302773
- Email: Roy.mashiach@gmail.com
Study Locations
-
-
-
Ramat Gan, Israel, 52503
- Recruiting
- The Chaim Sheba Medical Center,Tel Hashomer
-
Contact:
- Roy Mashiach, MD
- Phone Number: +97236130077
- Email: roy.mashiach@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients undergoing IVF after cesarean section
Exclusion Criteria:
- Patients who underwent CSD repair
- Patients with low ovarian reserve
- Patients with hydrosalpinges, endometriosis, adenomyosis, submucous fibroids or polyps
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nich Repair
Interventions to be administered:
|
Operative hysteroscopy for the repair of cesarean section defect is performed under general anesthesia.
the cervix is dilated and the cesarean section defect opened.
polypoid tissue is ablated
Other Names:
Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used.
vaginoscopy will be performed, followed by diagnostic hysteroscopy.
saline will be used as a distension media.
4.2 mm Storz hysteroscope will be used.
Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures. The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina.
Other Names:
Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
Other Names:
|
|
Sham Comparator: No Repair
Interventions to be administered:
|
Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used.
vaginoscopy will be performed, followed by diagnostic hysteroscopy.
saline will be used as a distension media.
4.2 mm Storz hysteroscope will be used.
Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures. The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina.
Other Names:
Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Embryo implantation rate
Time Frame: completion of two IVF cycles after randomization - approx. 2 months
|
Embryo implantation rate during IVF
|
completion of two IVF cycles after randomization - approx. 2 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fluid in Uterus
Time Frame: completion of two IVF cycles after randomization - approx. 2 months
|
Detection of fluid in the uterine cavity during menotropin stimulation in IVF treatment
|
completion of two IVF cycles after randomization - approx. 2 months
|
|
Correlation between size and type of the defect fluid accumulation
Time Frame: completion of two IVF cycles after randomization - approx. 2 months
|
Correlation between the size and type of the defect and the detection of fluid in the uterine cavity during menotropin stimulation in IVF treatment
|
completion of two IVF cycles after randomization - approx. 2 months
|
|
Correlation between the size and type of the defect and implantation rate during IVF treatment
Time Frame: completion of two IVF cycles after randomization - approx. 2 months
|
Correlation between the size and type of the defect and implantation rate during IVF treatment
|
completion of two IVF cycles after randomization - approx. 2 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SHEBA-14-1399-RM-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.